Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2013

View Archived Issues

AN-162 shows potent inhibitory effects in prostate cancer models

Flexible dosing of insulin degludec achieves glycemic control

Safety, tolerability and pharmacokinetics of ONO-9054 reported

A novel Neto1-KO mouse model with schizophrenia-related behavioral phenotype

Fourth pivotal trial of Celgene's apremilast in psoriatic arthritis meets endpoints

Biomarker modulation seen in phase I trial of AZD-1208

Novel Youai compounds active against RAS-mutant cancers

Lundbeck updates accomplishments of first quarter 2013

Calithera Biosciences targets GLS with novel compounds

Novel kappa opioid receptor agonist shows promise in animal models of dermatitis

Novo Nordisk recaps progress of first quarter 2013

Nimbus Discovery and Shire to codevelop treatments for lysosomal storage disorders

Data monitoring committee recommends continuation of phase III GRIPHON study

GSK updates on plans to share detailed clinical trial data

Zhejiang Huahai and Oncobiologics sign alliance for biosimilar monoclonal antibodies

Investigator initiated study in triple-negative breast cancer starts in Japan

Array BioPharma patents new tyrosine-protein kinase inhibitors

Portola's PRT-4445 shown to reverse anticoagulant activity of Eliquis in phase II study

Concordia Pharmaceuticals acquires the rights to Shionogi products

Celsus reports interim data from phase II contact dermatitis study

Techulon receives DARPA contract for therapies aimed at multi-drug resistant bacteria

Boehringer Ingelheim joins Structural Genomics Consortium on drug discovery projects

Abbott obtains CE Mark for diabetes diagnostic

Aviir launches cardiovascular genetic testing services

OMI obtains grants for myalgic encephalomyelitis/chronic fatigue syndrome

Inovio Pharmaceuticals discloses novel DNA vaccines for arenavirus

New beta-lactamase inhibitors synthesized by Therabor Pharmaceuticals

Aileron Therapeutics creates HIF-inhibiting Stapled Peptide for cancer therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...